New 10-year survival by stage estimates for East of England
CRUK, in partnership with the National Cancer Registration and Analysis Service (NCRAS) at Public Health England, have produced 10-year net survival by stage estimates for eight cancers for the East of England diagnosed between 2007 and 2017 (bowel, breast, kidney, lung, melanoma, ovary, prostate, uterus).
10-year survival gives an accurate reflection of the long-term survival for these cancers and this work focused on the differences in survival by stage at diagnosis. Some of the key results from this work show:
- 10-year survival is poorer if diagnosed at the latest stage compared with the earlier stages.
- 10-year survival was also generally lower than the 5-year estimates for that site and stage, with notable variation by site and stage.
- Melanoma, breast and prostate cancer 10-year survival estimates for those diagnosed at stage 1 remained high, whereas kidney and lung cancer 10-year estimates were significantly lower than 5-year survival at every stage.
- The relative difference between 5- and 10-year survival estimates generally increased by later stage at diagnosis.
Importantly, these results highlight the need for continued efforts to reduce the number of patients diagnosed at late stage and this is a key part of improving longer-term cancer outcomes.
The good historic stage data for this region of England enabled us to look at long-term survival analysis. This work also provides a baseline for future analysis once historic stage data is more complete for England, allowing country-wide long-term survival analysis to be undertaken.
Non age-standardised results were reported because small numbers in age/stage/site combinations made producing age-standardised 10-year survival estimates unfeasible. Estimates were also produced by sex (where appropriate) and age group (under and over 65 years).
Don’t forget, we have a range of statistics and information on cancer incidence, mortality, survival and risk factors (causes) by cancer type available online.